Skip to main content
. 2017 Mar 23;116(9):1177–1185. doi: 10.1038/bjc.2017.76

Figure 2.

Figure 2

Overall survival curves of GC patients according to expression of STMN1. (A and B) Kaplan–Meier overall survival analyses of GC patients with operable tumours treated with S-1 and 5-FU-based medicine as adjuvant therapies after surgery. High STMN1 expression was significantly associated with poor prognosis in patients treated with S-1 after surgery (P=0.0214). However, this relationship was not observed in patients treated with 5-FU-based adjuvant therapy (P=0.9657). (C and D) Kaplan–Meier overall survival analyses in patients with inoperable tumours treated with paclitaxel+S-1 (P=0.0082) and cisplatin+S-1 (P=0.3289) as first-line chemotherapy. High STMN1 expression correlated with poor survival in the paclitaxel+S-1-treated group (P=0.0082), but not in the cisplatin+S-1-treated group (P=0.3289).